Your browser doesn't support javascript.
loading
Assessment of Immunological Features in Muscle-Invasive Bladder Cancer Prognosis Using Ensemble Learning.
Gavriel, Christos G; Dimitriou, Neofytos; Brieu, Nicolas; Nearchou, Ines P; Arandjelovic, Ognjen; Schmidt, Günter; Harrison, David J; Caie, Peter D.
Afiliação
  • Gavriel CG; School of Medicine, University of St Andrews, St Andrews KY16 9TF, UK.
  • Dimitriou N; School of Computer Science, University of St Andrews, St Andrews KY16 9SX, UK.
  • Brieu N; Definiens GmbH, 80636 Munich, Germany.
  • Nearchou IP; School of Medicine, University of St Andrews, St Andrews KY16 9TF, UK.
  • Arandjelovic O; School of Computer Science, University of St Andrews, St Andrews KY16 9SX, UK.
  • Schmidt G; Definiens GmbH, 80636 Munich, Germany.
  • Harrison DJ; School of Medicine, University of St Andrews, St Andrews KY16 9TF, UK.
  • Caie PD; NHS Lothian, University Hospitals Division, Edinburgh EH16 4SA, UK.
Cancers (Basel) ; 13(7)2021 Apr 01.
Article em En | MEDLINE | ID: mdl-33915698
The clinical staging and prognosis of muscle-invasive bladder cancer (MIBC) routinely includes the assessment of patient tissue samples by a pathologist. Recent studies corroborate the importance of image analysis in identifying and quantifying immunological markers from tissue samples that can provide further insight into patient prognosis. In this paper, we apply multiplex immunofluorescence to MIBC tissue sections to capture whole-slide images and quantify potential prognostic markers related to lymphocytes, macrophages, tumour buds, and PD-L1. We propose a machine-learning-based approach for the prediction of 5 year prognosis with different combinations of image, clinical, and spatial features. An ensemble model comprising several functionally different models successfully stratifies MIBC patients into two risk groups with high statistical significance (p value < 1×10-5). Critical to improving MIBC survival rates, our method correctly classifies 71.4% of the patients who succumb to MIBC, which is significantly more than the 28.6% of the current clinical gold standard, the TNM staging system.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article